Investor Relations

Our Mission

Senti Bio was founded to create a new generation of smarter medicines that outsmart complex diseases using novel and unprecedented approaches.

Founded on Smart Science

Senti Bio is a clinical-stage company that has built a synthetic biology platform that enables it to program next-generation cell and gene therapies with Gene Circuits. These Gene Circuits, which are created from novel and proprietary combinations of DNA sequences, are designed to precisely kill cancer cells, spare healthy cells, increase specificity to target cells and control the expression of drugs even after administration. We are applying our Gene Circuit technologies to develop a pipeline of product candidates that use off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells.

Driven by Strong Leadership

Senti Bio is led by seasoned professionals with a passion for advancing life-changing therapies.

Chief Executive Officer and Co-founder, Dr. Tim Lu, is a pioneer in synthetic biology and has co-founded multiple therapeutics platform companies including Synlogic, Tango Therapeutics, Eligo Bioscience, BiomX and Engine Biosciences. Interim Chief Financial Officer and Treasurer, Yvonne Li, is a dynamic leader who inspires and empowers her team to achieve their full potential, cultivating a culture of trust and accountability that results in high-performing teams. Head of Research & Development and Chief Medical Officer, Dr. Kanya Rajangam, is an experienced biotechnology executive with an extensive track record of successfully developing products across multiple modalities including allogeneic cell therapies.